Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial
- 31 July 1992
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 20 (1), 24-30
- https://doi.org/10.1016/0735-1097(92)90132-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary EmbolismChest, 1990
- Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.Journal of Clinical Investigation, 1990
- UROKINASE VERSUS TISSUE PLASMINOGEN ACTIVATOR IN PULMONARY EMBOLISMThe Lancet, 1988
- RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISMThe Lancet, 1988
- Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes.Circulation, 1988
- Optimizing the bolus/infusion ratio for intravenous administration of urokinase in dogsThrombosis Research, 1988
- Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Urokinase in Acute Myocardial Infarction: Results of the German Activator Urokinase Study (GAUS)Journal of the American College of Cardiology, 1988
- Thrombolytic therapy of acute pulmonary embolism: Current status and future potentialJournal of the American College of Cardiology, 1987
- ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATORThe Lancet, 1986
- The sulphite precipitation method for fibrinogen measurement; Its use on small samples in the presence of fibrinogen degradation productsClinica Chimica Acta; International Journal of Clinical Chemistry, 1976